Preliminary clinical experience of the novel transcatheter aortic valve system Prizvalve® for the treatment of severe aortic stenosis.
10.3760/cma.j.cn112148-20211030-00937
- Author:
Jia Fu WEI
1
;
Hao Ran YANG
1
;
Yong PENG
1
;
Sen HE
1
;
Yong CHEN
1
;
Zhen Gang ZHAO
1
;
Wei MENG
2
;
Xuan ZHOU
3
;
Yu Jia LIANG
1
;
Wen Xia ZHOU
1
;
Xin WEI
1
;
Xi LI
1
;
Fei CHEN
1
;
Zhong Kai ZHU
1
;
Yi ZHANG
1
;
Jing Jing HE
1
;
Mao CHEN
1
;
Yuan FENG
1
Author Information
1. Department of Cardiology, West China Hospital, Sichuan University, Chengdu 610041, China.
2. Department of Cardiovascular Surgery, West China Hospital, Sichuan University, Chengdu 610041, China.
3. Department of Radiology, West China Hospital, Sichuan University, Chengdu 610041, China.
- Publication Type:Observational Study
- MeSH:
Aged;
Aged, 80 and over;
Aortic Valve;
Aortic Valve Stenosis/surgery*;
Heart Valve Prosthesis;
Heart Valve Prosthesis Implantation;
Humans;
Male;
Prospective Studies;
Transcatheter Aortic Valve Replacement/methods*;
Treatment Outcome
- From:
Chinese Journal of Cardiology
2022;50(2):137-141
- CountryChina
- Language:Chinese
-
Abstract:
Objective: To evaluate the safety and efficacy of transcatheter aortic valve implantation (TAVI) with the novel Prizvalve® system in treating severe aortic stenosis. Methods: This is a single-center, prospective, single-arm, observational study. A total of 11 patients with severe aortic stenosis with high risk or inappropriate for conventional surgical aortic valve replacement (SAVR) were included, and TAVI was achieved with the Prizvalve® system between March 2021 and May 2021 in West China Hospital. Transthoracic echocardiography (TTE) was performed immediately after prosthesis implantation to evaluate mean transaortic gradient and maximal transaortic velocity. The device success rate was calculated, which was defined as (1) the device being delivered via the access, deployed, implanted and withdrawn, (2) mean transaortic gradient<20 mmHg (1 mmHg=0.133 kPa) or a maximal transaortic velocity<3 m/s post TAVI, and without severe aortic regurgitation or paravalvular leak post TAVI. TTE was performed at 30 days after the surgery, and all-cause mortality as well as the major cardiovascular adverse events (including acute myocardial infarction, disabling hemorrhagic or ischemic stroke) up to 30 days post TAVI were analyzed. Results: The age of 11 included patients were (78.1±6.3) years, with 8 males. A total of 10 patients were with NYHA functional class Ⅲ or Ⅳ. Devices were delivered via the access, deployed, implanted and withdrawn successfully in all patients. Post-implant mean transaortic gradient was (7.55±4.08) mmHg and maximal transaortic velocity was (1.78±0.44) m/s, and both decreased significantly as compared to baseline levels (both P<0.05). No severe aortic regurgitation or paravalvular leak was observed post TAVI. Device success was achieved in all the 11 patients. No patient died or experienced major cardiovascular adverse events up to 30 days post TAVI. Mean transaortic gradient was (9.45±5.07) mmHg and maximal transaortic velocity was (2.05±0.42) m/s at 30 days post TAVI, which were similar as the values measured immediately post TAVI (both P>0.05). Conclusions: TAVI with the Prizvalve® system is a feasible and relatively safe procedure for patients with severe aortic stenosis and at high risk or inappropriate for SAVR. Further clinical studies could be launched to obtain more clinical experience with Prizvalve® system.
